Addex Therapeutics Ltd

Good day and thank you for standing by. Welcome to the ADEX Therapeutics Full Year 2024 Financial Results and Corporate Update Conference Call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be the question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone keypad. You will hear an automated message advising your hand is raised. To withdraw a question, please press star 1 1 again. If you wish to ask a question via the webcast, please use the Q&A box available on the webcast link at any time during the conference. Please be advised that this conference is being recorded. I would now like to hand the conference over to our first speaker today, Tim Dyer. Please go ahead.

Thank you. Hello, everyone. I would like to thank you all for attending our 2024 Full Year Financial Results Conference call. I'm here with Mikhail Kalinichev, our Head of Translational Science, who will provide an update on our R&D programs. I draw your attention to the press release and the financial statements issued earlier today, which are available on our website. I also draw your attention to our disclaimers. We will be making certain forward-looking statements that are based on the knowledge we have today. I will start this conference call by giving a quick overview of our recent activities and achievements before reviewing our pipeline. I will then hand over to Misha, who will review in more detail our mGluR5 negative allosteric modulator program for brain injury recovery, and our GABA-B positive allosteric modulator preclinical program for cough. I will then review our 2024 full-year financial results. Following that, we will open the call for Q&A. In 2024, we launched NeuroSterics with a 65 million US dollar Series A financing led by Perceptual Advisors and secured financing for our platform and preclinical portfolio. As part of this transaction, we received 5 million Swiss francs in cash and a 20% equity interest in NeuroSterics. We have made excellent progress in our GABA-B PAM program with the completion of the R&D phase, delivering multiple drug candidates. Our partner Indivior has selected a compound for development in substance use disorders and has started R&D enabling studies. We expect to be able to announce results from these studies soon. Under the terms of the agreement, ADDx is eligible for payment of up to $330 million on successful achievement pre-specified regulatory, clinical, and commercial milestones, as well as tiered royalties on the level of net sales from high single digits up to low double digits. Also, under the terms of the agreement, we have the right to select compounds for development in a predefined list of reserved indications. We have selected a compound to advance our own independent GABA B-PAM program for the treatment of chronic cough. We have substantially completed the preclinical profiling of our compounds for chronic cough and are currently working to secure funding to advance this program into the IND-enabling studies. Misha will be sharing some of this data with you later in our presentation. We've repositioned dipreglurant, our mGluR5 negative acetate modulator for brain injury recovery and are currently completing negotiations to access intellectual property covering the use of mGluR5 inhibitors in this interesting therapeutic indication. Misha will also talk more about this exciting program later in the presentation. Following the decision last year by our partner, Johnson & Johnson, to terminate development of ADX 71149, we have regained the rights to this Phase II asset with a high-value data set and significant materials. We have completed the year with 3.3 million Swiss francs of cash, which provides us with the cash runway through mid-2026. I'd like to highlight that the cash burn has been significantly reduced following the nearest Derrick spin-out transaction. However, current cash does not fund the progression of our unpartnered programs into the clinic. Now onto the pipeline. We continue to believe in DIP Regrant and executing our plans to reposition the development for brain injury recovery as mentioned. Our partner in Divior has selected GABA-BPAM drug candidate for development in substance use disorders and started IND-enabling studies. We're advancing an independent GABA-BPAM program for chronic cough and expect to start IND-enabling studies this year, subject to securing financing. And Neurosterix has made excellent progress in advancing its pipeline, including starting IND-enabling studies with its M4PAM program. Now I will hand over to Misha, who will give you some more details about our exciting portfolio.

Thanks, Tim. Hello, everyone. I will start by speaking about Dipraglurant and our plans for development in brain injury recovery. Following termination of the development of Dipraglurant in PD-LID, we embarked on a detailed evaluation of a number of potential indications of interest for future development. We have completed this exercise and have identified brain injury recovery as an interesting indication for the future development. We believe the differentiated profile of Dipramduran makes it particularly suitable for enhancing the impact of rehabilitation in traumatic brain injury and stroke patients. There is a large unmet medical need in post-stroke recovery and rehabilitation. Stroke is among leading causes of chronic, often lifelong disability, as it leads to motor, sensory, cognitive impairment, and multiple comorbidities. There are over 100 million stroke survivors worldwide, and the number is growing at the annual rate of 12 million. A variety of rehabilitation therapies are used with post-stroke patients, but the recovery is slow and often inadequate. there is an urgent need for pharmacological agents that can facilitate the recovery simulated by rehabilitation therapies. mGluR5 receptor is a suitable target to address post-stroke recovery, as it is densely expressed in the brain, involved in neural plasticity, and modulates excitatory-inhibitor equilibrium. In fact, Activation of Angular 5 has been observed in a range of neurological disorders, including stroke, where it plays a role in maladaptive rewiring of the brain following stroke. Inhibition of Angular 5, on the other hand, can facilitate adaptive rewiring of the brain, promoting neuroplasticity and creating of new functional pathways, moving the neural network towards the pre-lesion state. Exciting new evidence recently published in the journal Brain suggests that the negative allosteric modulator of FGOR5, MTEP, administered daily in rats following stroke results in a sustained and growing improvement in sensory motor function in comparison to vehicle treatment. Similar improvement in sensory motor function was observed in animals treated with our MGOR5NAM depremulant. MRI imaging of the resting state functional connectivity in post-stroke rodents shows that daily administration of M-TEP also stimulates intra- and inter-hemispheric connectivity in the brain disrupted by stroke. It is important to note that improvement in brain connectivity after stroke is known to correlate with functional recovery and is observed across species. Dipragluron is ideally suited to be used in tandem with rehabilitation therapies in post-stroke patients, as it has a fast onset of action and short half-life. It has shown good tolerability in healthy subjects, and in Parkinsonian patients, showing only mild to moderate CNS-related adverse effects. We have a drug product ready and a strong patent position and believe dipraglion can become a first-in-class drug to facilitate post-stroke recovery. We can also speculate that dipraglion mediated adaptive rewiring and facilitation of recovery following brain damage would also be seen in traumatic brain injury patients. Let me now switch to our GABA-B positive allosteric modulator program, which is partnered with Indivior. The aim of this collaboration is to deliver a better baclofen for substance use disorders. As a reminder, GABA-B receptor activation has been clinically validated in a number of disease areas using Buclofen, a GABA-B orthosteric agonist. Buclofen is an FDA-approved drug for treatment of spasticity and is widely used off-label to treat numerous diseases, including substance use disorders and others. However, Buclofen has a short half-life and comes with significant side effects, hampering its wider use. Thus, there is a strong need for a better Buclofen. We believe this can be achieved with positive allosteric modulator approach and their differentiated pharmacology, having the efficacy of baclofen, but longer half-life and improved side effect profile. Our partner in DVR has selected Alkalavipam drug candidate for development in substance use disorders and started ID-enabling studies. As part of our agreement with Indivior, ADDx has exercised its right to select a compound to advance its own independent GABA-B program for the treatment of chronic cough. I will now present this exciting opportunity. There is a strong rationale for developing GABA-B PAMPs for chronic cough. Chronic cough is a persistent cough that lasts for more than eight weeks and can be caused by a variety of factors including respiratory infections, asthma, allergies, and acid reflux, but also possibly by an overactive cough reflex. There is a large unmet medical need in novel antitrusive drugs as current standards of care are ineffective in 30% of patients or only moderately effective in up to 60% of patients. In addition, the current treatments carry risks of serious side effects. On the next slide, we show that GABA-B PAMs are likely to have a superior tolerability profile in comparison to the current standard of care and show no taste-related side effects as seen with the newly approved P2X3 inhibitor, Kefabixant. Support for using GABA-B PAM in treatment of chronic cough comes from the clinical evidence that Baclofen is used off-label in cough patients and from the anatomical evidence that GABA-B receptors are strongly expressed in airways and in the neural pathway regulating cough. Therefore, we believe that GABA-B PAMs could offer superior efficacy in cough patients. The pre-ID activities, including in vivo proof of concepts, non-GLP talks, and CMC have been completed, and our clinical candidate has shown favorable efficacy tolerability, and developability profiles. Our clinical candidate has demonstrated a consistent minimum effective dose of 1 mcg per kick and ED50 of 6 mcg per kick in cofrequency. No signs of tolerance were seen after subchromic dosing, and more than 30-fold safety margin was demonstrated based on tolerability biomarkers. The IND-enabling studies are planned to start this year. The next set of slides describes the in vivo proof-of-concept studies in models of cough. In a model of citric acid-induced coughing guinea pigs, acutely administered compound A delivered a robust anteclusive activity profile, reducing the cough number and increasing the latency to first cough. The anteclusive profile of BACMOS and NSAID model was more modest. as cough latency remained largely unchanged. In the same experiment, Compound A was better tolerated than Baclofen, as there were no marked changes in respiratory rate, body temperature, and plasma concentration of growth hormone, at up to 60 mcg. In contrast, Baclofen suppressed respiratory rate, reduced body temperature by near 2 degrees Celsius, and increased gross hormone concentration in plasma starting three mixed-booking dose. Thus, we believe we achieved our goal to discover a better baclofet for cough. In a model of citric acid-induced cough in guinea pigs, sub-chronically administered compound A showed signs of improved efficacy and potency and no signs of tolerance in comparison to an acute treatment. As expected, signs related to safety and tolerability of compound A remained largely unchanged under subchronic versus acute treatment regimens. In the model of ATP-potentiated citric acid cough in guinea pigs, in a head-to-head comparison experiment, acutely administered compound A and the P2X3 inhibitor had similar efficacy and tolerability profiles. In summary, We have selected a clinical candidate for chronic cough with a robust reproducible antithesis efficacy of 1-nick-per-kick and good PKPD. The compound showed a favorable developability profile in non-GLP tox studies performed in rats, dogs, and non-human primates. We are on track to start IND-enabling studies this year. This concludes our prepared remarks on the progress of our R&D program. Now, I hand it back to Tim.

Thanks, Risha. Now, before I move on to the financials, I would like to spend a few moments to speak about the NeuroSterix transaction. Due to the excellent progress made by our R&D team in advancing our unpartnered preclinical portfolio, our M4PAM, MDR7NAM, and MDR2 negative allosteric modulator programs reached a stage of development where they needed significant amounts of financing to progress into the clinic. Unfortunately, given the low market capitalization of ADEX, raising the amount of capital needed would have been extremely challenging and highly diluted to our shareholders. So we decided to spin out these programs and our platform into a new private company and raise the necessary capital directly into the new private company. We believe this is an excellent transaction for ADEX shareholders as it has secured 5 million Swiss francs for ADEX and removed the financing overhang on the ADEX stock. We have retained a 20% interest in NeuroSteric, so we can benefit from the upside from advancing the programs into the clinic, which is now secured by the $65 million capital from a high-quality investor syndicate led by Sector Advisors. As part of the transaction, we have divested our Allosteric Modulated Technology platform, including the majority of our staff. However, we have entered into a service agreement with NeuroSteric to ensure that we can access skills needed to execute on our business strategy. Now, for a review of the 2024 financials. Following the New Esterix transaction, we were required under IFRS to identify continuing operations related to our retained business and discontinued operations related to the divested business sold to New Esterix. All income and expense items related to the discontinuing operations have been reclassed under a specific line of the comprehensive loss called net profit or loss from discontinued operations. Starting with the income statements, which related to continuing operations, we recognized 400,000 of income in 2024 compared to 1.6 million in 2023. The decrease is primarily due to the completion of the funded research phase of our collaboration with Indivior in June of 2024. Continuing R&D expenses. of 0.9 million remain, primarily relate to our GABA B-PAM program, decreased by 0.2 million in 2024 compared to 2023 mainly due to the completion of the research phase of the individual collaboration. Continuing R&D, sorry, continuing G&A expenses of 2.3 million primarily relate to corporate development activities, decreased by 0.4 million swiss francs in 2024 compared to 2023 primarily due to the reduced dno costs the finance result lot result loss in 23 has turned to a small gain primarily due to a significant reduction in forex exposure as we are now holding most of our cash in swiss francs the share of the net loss of associates of 2.2 million relates to the 20% equity interest received as part of the consideration for the divestment of part of our business to Nearest Derricks, which is being accounted for using the equity method under IFRS 12. Under IFRS, we are required to recognise our share of their results. Now for the balance sheet. Our assets are primarily held in cash and we completed 2024 with 3.3 million Swiss francs. cash held in Swiss francs and U.S. dollars. Other current assets amounted to 0.2 million, primarily rate prepaid R&D costs. Our non-current assets of 7.1 million as of December 31, 2024, primarily relate to the 20% equity interest in Eurostex Group, recorded on the balance sheet under the equity method of accounting for associates. Current liabilities of 0.8 million as of December 31, 2024 decreased by 2.1 million compared to December 31, 2023 and primarily relate to R&D related accruals and payables. Non-current liabilities, 0.2 million as of December 31, 2024 decreased by 0.4 million compared to December 31, 2023. primarily due to the reduction in retirement benefit obligations following the transfer of staff to nearest areas. Now for the cash flow statement. At the end of 2024, the cash balance amounted to 3.3 million and decreased by 0.6 million compared to the beginning of the year. The 5 million gross proceeds received as part of the consideration received from the divestment or part of our business was offset by the operating costs of continuing activities. Now to summarize, we have made excellent progress in our GABA-V PAM program with our partner Indivior, selecting a compound for development and substance use disorders and starting IND enabling studies in the second half of 2024. New Aesthetics has made excellent progress with their lead M4 PAM drug candidates starting IND enabling studies in Q3 of 2024. Dipra Blanc is ready to restart clinical development, brain injury recovery. Our independent GABA B-PAM cough program has demonstrated excellent preclinical efficacy and tolerability with IND enabling studies ready to start. We're validating partnerships with industry, supported investors, and a strong balance sheet which puts us on a solid position to deliver on our strategic objectives.

This concludes the presentation and we will now open the call for questions. And now we're going to take our first question. And it comes to the line of Raghuram Selvaraju from HC Wainwright and Co. Your line is open.

Please ask a question. Excuse me, Raghuram, can you hear us? Your line is open for questions.

Dear participants, once again, if you wish to ask a question, please press star 11 on your telephone keypad and wait for a name to be announced. Alternatively, you can submit your questions via the webcast.

And we have on the line Raghuram Selvaraju from AC Wayne Wright & Co. Your line is open. Please ask your question. My apologies, Raghuram, we cannot hear you.

Dear speakers, we'll just give a moment for our participants to submit questions. And now we have another analyst. Just give us a moment. And the question comes from Peter Aylik from A-Consult. Your line is open. Please ask your question.

Good afternoon. I would like to know about NeuroSterics. I think that's a new company. Do they have other projects other than what you now sold to them? Thank you for an answer. Did you hear me?

Yes, thank you very much for your question. So NeuroSterics was actually founded by ADEX as a spin-out company. So we packaged up our platform, including facilities, people, and we put it into a new Swiss company, which we then sold to a U.S. LLC, which had been capitalized with cash and a capital commitment of $65 million from a syndicate of U.S. investors led by perceptible advisors. And the transaction involved buying the Swiss subsidiary for a mix of cash and equity. So ADEX received a 20% interest in the US LLC, plus $5 million of cash, and the rest of the $60 million is being deployed into the portfolio that was contributed into the neurosteric Swiss sub. And there are four programs. The lead program is a muscarinic M4-PAM, and then there is an mGluR7 negative modulator program, and also an mGluR2 negative allosteric modulator program, and then another program which is undisclosed at the very early stages of discovery. And they're all focused on neuropsychiatry, schizophrenia, mood disorders, and cognition. And an undisclosed CNS indication. Does that answer your question?

It does. But I guess that means that you have a lot of additional work just to sort of control the activities of neurosterics and of your 20% investment there, is that correct?

Well, NeurAsterix has its own team and most of, in fact, NeurAsterix has most of the old ADEX team plus new employees that have been recruited. And, you know, I am currently the CEO of NeurAsterix and the CEO of ADEX. And my role A CEO of ADEX is under a service agreement between New Asterix and ADEX.

Okay, that explains it. Thank you very much, Tim.

You're welcome. Thanks, Peter.

Thank you. Now we'll proceed with other questions. And it comes from the line of Raghuram Selvaraju from HC Wainwright & Co. Your line is open. Please ask your question.

Thanks for taking my question. I wanted to ask if it would be possible for you to enumerate how you are seeing the strategic environment essentially evolving for depraglurant, particularly within the context of neurorehabilitation, and if you could also comment on the potential ability to deploy depraglurant in neurorehabilitation contexts not involving post-stroke recovery. Thank you.

Misha, would you like to take this question? Yes, absolutely.

We are, as the program is our clinical asset and has shown very good tolerability both in healthy subjects and in patients with Parkinson's disease, it gives us an opportunity to perform a number of small clinical pharmacology studies aiming to assess improvement and modulation of plasticity in human subjects. We'll probably start with healthy volunteers and look at multiple sites of potential plasticity from motor cortex to sensory to midbrain to spinal cord also evaluate what type of treatment conditions is suitable and ideal for modulation, and then move forward with a similar study but performed in post-stroke patients. So this will be, as we see, two clinical pharmacology studies with specific questions very much focused on neuroplasticity. And we believe these studies will first confirm the modulation of plasticity in humans, in particular in postural patients, and will help us in designing proper phase 2A study on rehabilitation approaches. So that's a very overall summary of our clinical strategies.

And then secondly, if I may, I was wondering if you could comment on the recent developments in the neuropsych field, perhaps most notably the failure of the phase three trial of cobenfi as adjunctive treatment in schizophrenia and what implications this may have for future directions you pursue with one or more of the neurosterics lead assets. Thank you.

Yes, we saw the news, of course, and we believe that it has minimal, if any, impact on our strategy. We are pursuing the strategy of monotherapy. We believe in the target. We believe in the relevance of muscarinic M4 for psychosis, so it's not going to alter our plans at all.

And then lastly, Tim, I don't know if you are in a position to comment on this at this time, but I was wondering if you could offer us some idea of what, if anything, you plan to do with the compound that was returned to ADEX from J&J, and if you see any future development path for that asset. Thank you.

Yes, we are already discussing with a number of interested parties. We are We're doing our own evaluation. As you can imagine, this is a 20-year development in the hands of J&J. It's a very, very high-quality compound with a lot of data, a lot of material, about 280 kilograms of API has been transferred to us. And this is significant material for us to play with. So we're definitely looking to enter a number of collaborations to explore areas that could be pursued with the compounds.

Thank you very much.

Thank you.

Dear participants, as a reminder, if you wish to ask a question, please press star 11 on your telephone keypad. Alternatively, you can submit your questions via the webcast. Dear speakers, we'll just give a moment for our analyst to submit any questions.

Thank you, ladies and gentlemen.

This brings the main part of our conference to close, and I would like to hand back to Tim Dyer for closing remarks.

Well, thank you, everyone, for attending the 2024 full-year results conference call, and I wish you all a very nice day, and we look forward to speaking to you again soon.

This concludes today's conference call. Thank you for participating. You may now disconnect. Have a nice day.